Harmony Biosciences Holdings, Inc. (HRMY)Healthcare | Biotechnology | Plymouth Meeting, United States | NasdaqGM
37.51 USD
+0.48
(1.296%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:13 a.m. EDT
The investment case here is a classic biotech value trap masked by impressive recent earnings growth. Fundamentally, the company is executing well with +30% revenue growth and expanding margins, supported by a healthy balance sheet and strong cash generation. However, the market has priced in a severe structural decline, with the stock down nearly 23% over the last five years and still trailing its 200-day average. This disconnect creates a compelling long-term thesis for patient capital willing to wait for the multiple expansion, but the short-term outlook remains precarious. The options market is screaming caution, with heavy positioning in deep out-of-the-money puts indicating a fear of a sharp drop. Until the price action stabilizes and breaks above key resistance, the momentum signal is weak, keeping the short-term rating neutral despite the solid underlying business quality. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.106117 |
| AutoETS | 0.106117 |
| AutoTheta | 0.106139 |
| MSTL | 0.107465 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 3.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.304 |
| Excess Kurtosis | 0.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 16.031 |
| Revenue per Share | 16.626 |
| Market Cap | 2,184,446,976 |
| Trailing P/E | 11.95 |
| Forward P/E | 5.36 |
| Beta | 1.01 |
| Profit Margins | 18.88% |
| Website | https://www.harmonybiosciences.com |
As of Oct. 10, 2026, 6:13 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by massive open interest in deep out-of-the-money puts (strikes 20 and 27.5) compared to negligible call volume. While there is some aggressive buying of calls at the $55 strike for April expiration, the overwhelming majority of option flow is concentrated in protective puts, suggesting a 'bet against' or hedging strategy rather than a bullish momentum play.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44547212 |
| Address1 | 630 West Germantown Pike |
| Address2 | Suite 215 |
| All Time High | 62.085 |
| All Time Low | 18.611 |
| Ask | 49.31 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 898,830 |
| Average Daily Volume3 Month | 907,348 |
| Average Volume | 907,348 |
| Average Volume10Days | 898,830 |
| Beta | 1.009 |
| Bid | 27.98 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 17.193 |
| City | Plymouth Meeting |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 37.51 |
| Current Ratio | 3.479 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 38.31 |
| Day Low | 36.92 |
| Debt To Equity | 16.031 |
| Display Name | Harmony Biosciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,846,600 |
| Earnings Call Timestamp Start | 1,785,846,600 |
| Earnings Growth | 0.882 |
| Earnings Quarterly Growth | 0.896 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | 255,987,008 |
| Ebitda Margins | 0.26668 |
| Enterprise To Ebitda | 6.551 |
| Enterprise To Revenue | 1.747 |
| Enterprise Value | 1,676,847,104 |
| Eps Current Year | 5.22166 |
| Eps Forward | 7.00454 |
| Eps Trailing Twelve Months | 3.14 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 39.9956 |
| Fifty Day Average Change | -2.4856033 |
| Fifty Day Average Change Percent | -0.062146917 |
| Fifty Two Week Change Percent | 44.54721 |
| Fifty Two Week High | 43.49 |
| Fifty Two Week High Change | -5.9800034 |
| Fifty Two Week High Change Percent | -0.13750295 |
| Fifty Two Week Low | 25.52 |
| Fifty Two Week Low Change | 11.989998 |
| Fifty Two Week Low Change Percent | 0.4698275 |
| Fifty Two Week Range | 25.52 - 43.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,597,843,800,000 |
| Float Shares | 52,094,783 |
| Forward Eps | 7.00454 |
| Forward P E | 5.3550982 |
| Free Cashflow | 182,835,504 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 293 |
| Fullday Change | 0.47999954 |
| Fullday Change Percent | 1.2962451 |
| Fullday Price | 37.51 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.75424004 |
| Gross Profits | 723,993,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01217 |
| Held Percent Institutions | 0.99605006 |
| Implied Shares Outstanding | 58,236,393 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-19 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. |
| Long Name | Harmony Biosciences Holdings, Inc. |
| Market | us_market |
| Market Cap | 2,184,446,976 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_679038073 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 181,270,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,358,282,734 |
| Number Of Analyst Opinions | 11 |
| Open | 37.16 |
| Operating Cashflow | 355,076,992 |
| Operating Margins | 0.34183997 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 484 539 9800 |
| Previous Close | 37.03 |
| Price Eps Current Year | 7.183539 |
| Price Hint | 2 |
| Price To Book | 2.1817017 |
| Price To Sales Trailing12 Months | 2.2757075 |
| Profit Margins | 0.18884 |
| Quick Ratio | 3.327 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.47999954 |
| Regular Market Change Percent | 1.2962451 |
| Regular Market Day High | 38.31 |
| Regular Market Day Low | 36.92 |
| Regular Market Day Range | 36.92 - 38.31 |
| Regular Market Open | 37.16 |
| Regular Market Previous Close | 37.03 |
| Regular Market Price | 37.51 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 972,227 |
| Return On Assets | 0.1162 |
| Return On Equity | 0.20456 |
| Revenue Growth | 0.303 |
| Revenue Per Share | 16.626 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 58,236,393 |
| Shares Percent Shares Out | 0.095 |
| Shares Short | 5,532,301 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,164,996 |
| Short Name | Harmony Biosciences Holdings, I |
| Short Percent Of Float | 0.1269 |
| Short Ratio | 5.12 |
| Source Interval | 15 |
| State | PA |
| Symbol | HRMY |
| Target High Price | 70.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 47.63636 |
| Target Median Price | 50.0 |
| Total Cash | 667,790,976 |
| Total Cash Per Share | 11.467 |
| Total Debt | 160,191,008 |
| Total Revenue | 959,897,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.14 |
| Trailing P E | 11.945859 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 34.662 |
| Two Hundred Day Average Change | 2.8479996 |
| Two Hundred Day Average Change Percent | 0.0821649 |
| Type Disp | Equity |
| Volume | 972,227 |
| Website | https://www.harmonybiosciences.com |
| Zip | 19,462 |